Market Place
Sourcing Support
ReAlta`s Shows Positive Data in Acute Graft-Versus-Host Disease
08 Dec 2024 //
BUSINESSWIRE
ReAlta Appoints Dr. Lewis T. “Rusty” Williams as Board Chairman
21 Nov 2024 //
BUSINESSWIRE
ReAlta Life Sciences to Present RLS-0071 Data in aGVHD at ASH
05 Nov 2024 //
BUSINESSWIRE
ReAlta Doses First Patient In Phase 2 RLS-0071 GVHD Study
23 Sep 2024 //
BUSINESSWIRE
ReAlta Life Sciences Appoints Peter Ho, Ph.D., as Head of Business Development
04 Sep 2024 //
BUSINESSWIRE
Biopharmaceutical Company ReAlta Hires New CEO, R&D Head
23 Aug 2024 //
CONTRACT PHARMA
ReAlta Life Sciences Appoints New CEO And Chief R&D Officer
22 Aug 2024 //
BUSINESSWIRE
ReAlta`s RLS-0071 Gets FDA Orphan Drug And Fast Track Designations
19 Aug 2024 //
BUSINESSWIRE
ReAlta Announces Collaboration with the NIAID to Evaluate RLS-0071 for ARS
28 Mar 2024 //
BUSINESSWIRE
ReAlta Life Announces Dosing of First Patient in Phase 2 Trial of RLS-0071
21 Feb 2024 //
BUSINESSWIRE
ReAlta Life Sciences Strengthens Board of Directors
24 Jan 2024 //
BUSINESSWIRE
ReAlta Life Sciences Strengthens Board of Directors
03 Jan 2024 //
BUSINESSWIRE
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071
24 Oct 2023 //
BUSINESSWIRE
ReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071
06 Sep 2023 //
BUSINESSWIRE
ReAlta Announces Poster Presentation at the European Respiratory Society
05 Sep 2023 //
BUSINESSWIRE
ReAlta Life Sciences Doses First Patient in Phase 2 STAR-Study of RLS-0071
01 Aug 2023 //
BUSINESSWIRE
ReAlta Life Sciences Announces Poster Presentation at Annual Meeting
30 Mar 2023 //
BUSINESSWIRE
FDA Grants FTD to ReAlta’s RLS-0071 for Hypoxic-Ischemic Encephalopathy
23 Jun 2022 //
BUSINESSWIRE
ReAlta doses first subjects in Phase Ib severe asthma therapy trial
02 Jun 2022 //
CLINICALTRIALSARENA
ReAlta Life Sciences Announces Poster Presentation at the AAN 2022
04 Mar 2022 //
BUSINESSWIRE
ReAlta Life Sciences Receives $3.2 Million Grant from Virginia Catalyst
08 Jun 2021 //
BIOSPACE
Statewide Collaboration Leads the Way in Closing Gaps in Vaccine Administration
18 May 2021 //
BUSINESSWIRE
ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071
18 May 2021 //
BUSINESSWIRE
ReAlta Life Sciences Doses First Subject in Ph 1 Volunteers of RLS-0071
16 Feb 2021 //
BUSINESSWIRE
ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071
03 Dec 2020 //
BUSINESSWIRE
ReAlta Life Announces USFDA Clearance of First Investigational NDA for RLS-0071
27 Jul 2020 //
BUSINESSWIRE
ReAlta Life Sciences Closes $14 Million Series A2 Financing
21 Apr 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.